SecBot SecBot
PREC14A ·Filed Apr 17, 2026

PCRX

Pacira BioSciences, Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago SEC0001104659-26-044908
Notable filing: PREC14A
Actionable Insight ◆ Mixed

Investors should monitor the outcome of the contested board election, as a shift in board composition could lead to changes in capital allocation and strategy. The upcoming 2026 clinical data readouts are critical catalysts that could validate the company's pipeline progress and influence stock performance.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.90
T+0 close · Apr 17, 2026 · via day close
Latest settled
+1.73%
T+60 · $25.33
Vs SPY
−5.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $24.90entry
  2. T+1 · 7mo ago −1.04%α −0.39% · $24.64
  3. T+5 · 7mo ago +2.61%α +1.70% · $25.55
  4. T+20 · 6mo ago −9.88%α −14.08% · $22.44
  5. T+60 · 4mo ago +1.73%α −5.05% · $25.33
Loading chart...

Executive Summary

Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.2% year-over-year volume growth for EXPAREL and record-high gross margins. The company is entering a data-rich period with key 2026 catalysts from its pipeline. However, the annual meeting is contested, with activist investor DOMA Perpetual nominating three director candidates, challenging the board's composition and capital allocation strategy.

Key Facts

  • EXPAREL achieved 6.2% year-over-year volume growth in 2025, with 8% growth in the second half.
  • The company delivered record-high 2025 GAAP and Non-GAAP Gross Margins of 79% and 81%, respectively.
  • Pacira returned $150 million to stockholders through share repurchases in 2025.
  • The company is entering a data-rich period with key 2026 readouts expected for PCRX-201, ZILRETTA in shoulder OA, and iovera in spasticity.
  • Activist investor DOMA Perpetual has nominated three director candidates, leading to a contested election at the annual meeting.

Financial Impact

The company repurchased $150 million in shares in 2025 and has a new $300 million authorization. The 5x30 strategy aims for double-digit compounded annual growth and a five-percentage point gross margin improvement by 2030.

revenuegross_margindilutiondebt

Risk Factors

  • The contested board election creates uncertainty around future strategic direction.
  • The company faces potential generic competition for EXPAREL starting in 2030, despite a volume-limited settlement.
  • The stock price performance in 2025 was negatively impacted by patent litigation, which could affect investor sentiment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
PREC14A Filing (Primary)0001104659-26-044908
Document: 0001104659-26-044908-index-headers.html0001104659-26-044908
Document: 0001104659-26-044908-index.html0001104659-26-044908
Document: 0001104659-26-044908.txt0001104659-26-044908

Track record

29 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  2. Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  3. Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  5. Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  6. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  7. Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  8. Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
  9. Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
  10. Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026